JP2021512920A5 - - Google Patents
Info
- Publication number
- JP2021512920A5 JP2021512920A5 JP2020542858A JP2020542858A JP2021512920A5 JP 2021512920 A5 JP2021512920 A5 JP 2021512920A5 JP 2020542858 A JP2020542858 A JP 2020542858A JP 2020542858 A JP2020542858 A JP 2020542858A JP 2021512920 A5 JP2021512920 A5 JP 2021512920A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutically acceptable
- carboxylic acid
- acceptable salt
- difluoromethylenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US62/628,020 | 2018-02-08 | ||
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| US62/628,541 | 2018-02-09 | ||
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021512920A JP2021512920A (ja) | 2021-05-20 |
| JP2021512920A5 true JP2021512920A5 (https=) | 2022-02-15 |
Family
ID=67475310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542858A Pending JP2021512920A (ja) | 2018-02-08 | 2019-02-08 | 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (https=) |
| EP (1) | EP3735237A4 (https=) |
| JP (1) | JP2021512920A (https=) |
| KR (3) | KR20250167147A (https=) |
| CN (1) | CN112261938A (https=) |
| AU (1) | AU2019216742B2 (https=) |
| CA (1) | CA3090258A1 (https=) |
| IL (1) | IL276287A (https=) |
| MX (1) | MX2020008359A (https=) |
| WO (1) | WO2019157273A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016342027B2 (en) | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| JP2021519753A (ja) * | 2018-03-29 | 2021-08-12 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| JP2009517393A (ja) | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) * | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| WO2013087090A1 (en) * | 2011-12-12 | 2013-06-20 | Auris Medical Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| JP6841821B2 (ja) | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| EP4692048A3 (en) | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
-
2019
- 2019-02-08 KR KR1020257038778A patent/KR20250167147A/ko active Pending
- 2019-02-08 KR KR1020247034793A patent/KR20240154700A/ko not_active Ceased
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Ceased
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en not_active Ceased
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
-
2020
- 2020-07-26 IL IL276287A patent/IL276287A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512920A5 (https=) | ||
| JP2019031502A5 (https=) | ||
| KR101451414B1 (ko) | 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도 | |
| CN1307998C (zh) | 用于局部治疗美尼埃尔氏疾病、耳鸣和/或听力损伤的新方法和组合物 | |
| JP2007530622A5 (https=) | ||
| JP2009510047A (ja) | 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法 | |
| JP2017509686A5 (https=) | ||
| JP2008538115A5 (https=) | ||
| JP2023076465A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2013544850A5 (https=) | ||
| JP2013515752A5 (https=) | ||
| JP2004527551A (ja) | エナンチオ純粋なエスシタロプラムの使用方法 | |
| JP2024517738A5 (https=) | ||
| JP2019512528A5 (https=) | ||
| JP2003504303A5 (https=) | ||
| JP2017535613A5 (https=) | ||
| NZ600478A (en) | Beta-carbolines for use in the treatment of hearing loss and vertigo | |
| JP2013523769A5 (https=) | ||
| JP2019537582A5 (https=) | ||
| JP2005508872A5 (https=) | ||
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| JP2007509960A5 (https=) | ||
| JP2022506113A5 (https=) | ||
| RU2008127882A (ru) | Лечение пищевода барретта | |
| JP2007505156A5 (https=) |